ArticleClinical ophthalmology (Auckland, N.Z.)2026
Visual and Patient-Reported Outcomes of a Non-Diffractive Extended Depth-of-Focus Intraocular Lens with Micro-Monovision in Eyes with Early Macular Pathology.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate visual and patient-reported outcomes after bilateral implantation of a non-diffractive extended depth of focus (EDOF) IOL (AcrySof IQ Vivity, Alcon) in patients with early macular pathology. Design: Single-site, prospective, non-comparative pilot cohort study. Patients and Methods: The study included 20 patients (40 eyes) undergoing bilateral cataract surgery with at least one eye with early-stage macular pathology, specifically age-related macular degeneration (AREDS category 2) or epiretinal membrane (stage 0). All patients received bilateral implantation of the non-diffractive EDOF IOL targeted for micro-monovision. Primary outcomes were monocular corrected distance visual acuity (CDVA) and distance-corrected intermediate visual acuity (DCIVA) at 3 months. Secondary outcomes included binocular CDVA, DCIVA, and distance-corrected near visual acuity (DCNVA); uncorrected distance, intermediate and near visual acuity (UDVA, UIVA, UNVA); refractive outcomes; contrast sensitivity and patient-reported outcomes, including satisfaction and visual disturbances. Results: At 3 months, median (IQR) monocular CDVA, DCIVA, and DCNVA were 0.00 (0.00-0.10), 0.18 (0.08-0.28), and 0.40 (0.30-0.50) logMAR, respectively. Binocular CDVA, DCIVA, and DCNVA were 0.00 (0.00-0.00), 0.13 (0.08-0.18), and 0.35 (0.22-0.40). Binocular UDVA, UIVA, and UNVA were 0.00 (0.00-0.00), 0.08 (-0.01-0.11), and 0.30 (0.20-0.33) logMAR, respectively. 90% of dominant and 95% of non-dominant eyes were within ±0.50 D of the intended outcome. Photopic contrast sensitivity was within normal range, while mesopic values were near the lower end of normal. Most patients (90%) were satisfied with their vision. Visual disturbances were low in frequency, severity, and bothersomeness, with median Rasch-calibrated scores of 32, 27, and 29, respectively. Conclusion: In patients with early macular pathology, bilateral implantation of a non-diffractive EDOF IOL demonstrated promising distance and intermediate vision, favorable near visual outcomes, and high patient satisfaction with minimal visual disturbances. Larger, prospective, comparative studies are warranted to define candidacy for patients with macular pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.